TL;DR: The Centers for Medicare & Medicaid Services modified NCD 66, the National Coverage Determination governing Medicare coverage of local hyperthermia for cancer treatment, effective January 9, 2026. Here's what billing teams need to know.
This CMS hyperthermia coverage policy update clarifies exactly when local hyperthermia is—and isn't—a covered Medicare benefit. The policy does not list specific CPT or HCPCS codes, which creates a real documentation burden for your team. If you bill hyperthermia services for oncology patients, you need to understand the narrow coverage window this policy defines before you submit another claim.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Hyperthermia for Treatment of Cancer |
| Policy Code | NCD 66 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Medium |
| Specialties Affected | Radiation Oncology, Medical Oncology, Dermatology, Surgical Oncology |
| Key Action | Confirm every hyperthermia claim pairs with radiation therapy for a covered superficial malignancy — not chemotherapy, not standalone treatment |
CMS Local Hyperthermia Cancer Coverage Criteria and Medical Necessity Requirements 2026
NCD 66 is the National Coverage Determination governing whether Medicare pays for local hyperthermia when used in cancer treatment. Local hyperthermia uses heat to make tumors more susceptible to therapy. On its own, that sounds straightforward. The coverage criteria are tight, though, and the exclusions are specific.
Here's what the updated CMS hyperthermia coverage policy actually says:
Medicare covers local hyperthermia when all three of these conditions are met:
| # | Covered Indication |
|---|---|
| 1 | It is local hyperthermia (not regional or whole-body) |
| 2 | It is used in connection with radiation therapy |
| 3 | It treats primary or metastatic cutaneous or subcutaneous superficial malignancies |
That's the full covered population. If your patient's case falls outside those three criteria, you're looking at a claim denial before the chart even leaves the office.
The medical necessity case here is narrow by design. CMS isn't saying hyperthermia doesn't work—they're saying the evidence supports coverage only for this specific combination: local application, paired with radiation, for superficial skin and subcutaneous tumors. If your radiation oncology team is using heat therapy alongside radiation for a cutaneous melanoma metastasis or a primary squamous cell carcinoma of the skin, that's a covered service. Everything else is not.
Prior authorization requirements are not explicitly called out in NCD 66 as updated, but that doesn't mean your Medicare Administrative Contractor won't apply additional scrutiny. MACs can and do issue local coverage determinations that layer onto NCDs. Check your MAC's LCDs before January 9, 2026 to see if any regional guidance tightens these criteria further.
Reimbursement for covered hyperthermia services depends entirely on correct claim submission with documentation that ties the service to radiation therapy for a qualifying superficial malignancy. Weak documentation—even for a technically covered case—will get you denied.
CMS Local Hyperthermia Exclusions and Non-Covered Indications
This is where NCD 66 is most useful to your billing team. The policy is explicit about what Medicare will not pay for. Memorize these two exclusions.
Hyperthermia used alone is not covered. If the physician applies heat therapy without pairing it to radiation treatment, Medicare won't pay—regardless of the cancer type or the clinical rationale.
Hyperthermia used with chemotherapy is not covered. This is the exclusion that catches billing teams off guard. A patient receiving systemic chemotherapy who also receives local hyperthermia has no Medicare coverage for the hyperthermia under NCD 66. The coverage policy is radiation-specific. Chemo plus heat is excluded, full stop.
The real issue here is documentation clarity at the point of service. If a patient is receiving both radiation and chemotherapy—which is common in oncology—your documentation needs to make absolutely clear that the hyperthermia is administered in connection with the radiation component, not the chemotherapy. Ambiguous records will trigger denials and likely a medical necessity review.
This matters because combined-modality treatment is standard in several cancer types. Your oncology billing team and your medical director need to talk about how operative notes and treatment records document the relationship between hyperthermia and each treatment modality. Get that conversation scheduled before the January 9, 2026 effective date.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Local hyperthermia + radiation therapy for primary cutaneous malignancy | Covered | Not specified in NCD 66 | Must be local application; documentation must tie to radiation, not chemo |
| Local hyperthermia + radiation therapy for metastatic cutaneous malignancy | Covered | Not specified in NCD 66 | Same documentation requirements apply |
| Local hyperthermia + radiation therapy for subcutaneous superficial malignancy | Covered | Not specified in NCD 66 | Depth of lesion matters — must be subcutaneous/superficial |
| Local hyperthermia used alone (no radiation or chemo) | Not Covered | Not specified in NCD 66 | No coverage regardless of cancer type or stage |
| Local hyperthermia used with chemotherapy (no radiation) | Not Covered | Not specified in NCD 66 | Explicitly excluded under NCD 66 |
| Regional or whole-body hyperthermia | Not addressed in NCD 66 | Not specified in NCD 66 | NCD 66 applies only to local hyperthermia; check applicable LCDs |
CMS Hyperthermia Billing Guidelines and Action Items 2026
The coverage policy is clear. Your billing process needs to match it. Here are the specific steps to take before January 9, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your active hyperthermia claims for radiation pairing. Pull every open or recently submitted hyperthermia claim. Confirm each one shows radiation therapy as the concurrent treatment. If you find any claims where the documented pairing is chemotherapy or no treatment at all, flag those for your compliance officer before they age further. |
| 2 | Update your charge capture workflows to require radiation therapy documentation. Hyperthermia billing should trigger an automatic check: Is the patient currently receiving radiation therapy for a cutaneous or subcutaneous malignancy? If the answer is no, the charge shouldn't move forward without escalation. |
| 3 | Check your MAC's local coverage determinations. NCD 66 sets the national floor. Your Medicare Administrative Contractor may have issued an LCD with tighter criteria, additional documentation requirements, or specific code guidance. Search your MAC's website using the keyword "hyperthermia" and review any active LCDs before the January 9, 2026 effective date. |
| 4 | Work with your medical director to update operative notes and treatment documentation templates. Every hyperthermia treatment record should explicitly state: (a) the malignancy being treated is cutaneous or subcutaneous, (b) hyperthermia is being administered in connection with radiation therapy, and (c) the treatment is local hyperthermia. This language directly mirrors NCD 66's coverage criteria and makes a medical necessity review much easier to defend. |
| 5 | Identify mixed-modality patients and flag them for case-by-case review. Patients receiving both radiation and chemotherapy are your highest claim denial risk under this policy. The heat therapy has to tie to radiation—not chemo. If your documentation doesn't make that clear, CMS has grounds to deny. Ask your compliance officer to build a review protocol for these cases. |
| 6 | Do not bill hyperthermia as a standalone service. This sounds obvious, but standalone hyperthermia claims do get submitted—usually when a coder misses a missing radiation therapy charge or when charges are entered on different dates of service. If you see hyperthermia without a corresponding radiation therapy charge in the same claim period, stop and investigate before submitting. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Hyperthermia Under NCD 66
A Note on Code Availability
The Centers for Medicare & Medicaid Services did not list specific CPT, HCPCS, or ICD-10 codes in the published NCD 66 policy document. This is unusual and creates a real gap for hyperthermia billing teams.
The absence of codes in the NCD doesn't mean there are no applicable codes—it means you need to do additional research to identify them. Here's where to look:
- Your MAC's LCD: Local coverage determinations frequently include the CPT and ICD-10 codes that correspond to an NCD's indications. Search your MAC's coverage database for hyperthermia.
- CMS Claims Processing Instructions: NCD 66 cross-references Claims Processing Instructions, which may include code-level guidance. Pull those instructions and review them against your current charge master.
- AMA CPT codebook: Hyperthermia treatment codes do exist in the CPT system. Your coding team should identify the correct codes for local hyperthermia under radiation therapy and confirm those codes are mapped correctly in your system.
Do not assume the codes you're currently using are correct without verifying against MAC guidance. If you're not certain which codes apply to your patient population, loop in your billing consultant before the January 9, 2026 effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.